港股異動丨凱萊英AH均高開 擬收購Snapdragon公司剩餘股權 其將成為公司海外研發平台
格隆匯2月14日丨凱萊英(06821.HK)高開近4%,報242.2港元;凱萊英(002821.SZ)亦高開逾4%。凱萊英近日同Snapdragon公司及股東代表等各方簽署了《合併協議》。據此,公司擬通過合併方式以自有資金約5,794萬美元收購Snapdragon公司除凱萊英已持有的股權外其他49名股東所持有的股權。本次收購完成後,凱萊英將持有Snapdragon公司100%股權。Snapdragon將作為公司的海外研發平台,進一步加強公司於小分子CDMO領域的研發實力,尤其是在連續生產技術方面,並透過Snapdragon現有客户網絡擴大公司的海外佈局。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.